AKT3 is altered in 1.34% of malignant solid tumor patients with AKT3 Amplification present in 0.31% of all malignant solid tumor patients [4].

AKT3 Amplification is an inclusion criterion in 14 clinical trials for malignant solid tumor, of which 11 are open and 3 are closed. Of the trials that contain AKT3 Amplification and malignant solid tumor as inclusion criteria, 5 are phase 1 (3 open), 3 are phase 1/phase 2 (3 open), and 6 are phase 2 (5 open) [5].

AKT3 is altered in 1.55% of breast carcinoma patients with AKT3 Amplification present in 0.73% of all breast carcinoma patients [4].

AKT3 Amplification is an inclusion criterion in 6 clinical trials for breast carcinoma, of which 6 are open and 0 are closed. Of the trials that contain AKT3 Amplification and breast carcinoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [5].

AKT3 is altered in 1.51% of non-small cell lung carcinoma patients with AKT3 Amplification present in 0.09% of all non-small cell lung carcinoma patients [4].

AKT3 Amplification is an inclusion criterion in 3 clinical trials for non-small cell lung carcinoma, of which 2 are open and 1 is closed. Of the trials that contain AKT3 Amplification and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (0 open) [5].

AKT3 is altered in 1.12% of non-hodgkin lymphoma patients with AKT3 Amplification present in 0.07% of all non-hodgkin lymphoma patients [4].

AKT3 Amplification is an inclusion criterion in 3 clinical trials for non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain AKT3 Amplification and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [5].

AKT3 is altered in 1.5% of colorectal carcinoma patients with AKT3 Amplification present in 0.02% of all colorectal carcinoma patients [4].

AKT3 Amplification is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 3 are open and 0 are closed. Of the trials that contain AKT3 Amplification and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [5].

AKT3 is altered in 2.18% of melanoma patients with AKT3 Amplification present in 0.83% of all melanoma patients [4].

AKT3 Amplification is an inclusion criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain AKT3 Amplification and melanoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].

AKT3 is altered in 1.33% of head and neck squamous cell carcinoma patients [4].

AKT3 Amplification is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain AKT3 Amplification and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [5].

AKT3 is altered in 0.57% of hepatocellular carcinoma patients [4].

AKT3 Amplification is an inclusion criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT3 Amplification and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

AKT3 is altered in 0.22% of renal cell carcinoma patients [4].

AKT3 Amplification is an inclusion criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT3 Amplification and renal cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].

AKT3 is altered in 0.98% of squamous cell lung carcinoma patients [4].

AKT3 Amplification is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT3 Amplification and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

AKT3 is altered in 1.25% of pecoma patients with AKT3 Amplification present in 1.27% of all pecoma patients [4].

AKT3 Amplification is an inclusion criterion in 1 clinical trial for pecoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 Amplification and pecoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

AKT3 is altered in 1.19% of peritoneal mesothelioma patients with AKT3 Amplification present in 1.25% of all peritoneal mesothelioma patients [4].

AKT3 Amplification is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 Amplification and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].

AKT3 is altered in 1.8% of small cell lung carcinoma patients with AKT3 Amplification present in 0.69% of all small cell lung carcinoma patients [4].

AKT3 Amplification is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 Amplification and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

AKT3 is altered in 1.27% of malignant glioma patients with AKT3 Amplification present in 0.59% of all malignant glioma patients [4].

AKT3 Amplification is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 Amplification and malignant glioma as inclusion criteria, 1 is early phase 1 (1 open) [5].

AKT3 is altered in 3.85% of endometrial carcinoma patients with AKT3 Amplification present in 0.58% of all endometrial carcinoma patients [4].

AKT3 Amplification is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 Amplification and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

AKT3 is altered in 1.15% of ovarian carcinoma patients with AKT3 Amplification present in 0.46% of all ovarian carcinoma patients [4].

AKT3 Amplification is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 Amplification and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

AKT3 is altered in 1.28% of cancer patients with AKT3 Amplification present in 0.29% of all cancer patients [4].

AKT3 Amplification is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains AKT3 Amplification and cancer as inclusion criteria, 1 is phase 1 (1 open) [5].

AKT3 is altered in 0.9% of pancreatic carcinoma patients with AKT3 Amplification present in 0.2% of all pancreatic carcinoma patients [4].

AKT3 Amplification is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 Amplification and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

AKT3 is altered in 0.53% of prostate carcinoma patients with AKT3 Amplification present in 0.19% of all prostate carcinoma patients [4].

AKT3 Amplification is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 Amplification and prostate carcinoma as inclusion criteria, 1 is phase 3 (1 open) [5].

AKT3 is altered in 1.47% of urothelial carcinoma patients with AKT3 Amplification present in 0.18% of all urothelial carcinoma patients [4].

AKT3 Amplification is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 Amplification and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

AKT3 is altered in 1.31% of B-cell non-hodgkin lymphoma patients with AKT3 Amplification present in 0.09% of all B-cell non-hodgkin lymphoma patients [4].

AKT3 Amplification is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 Amplification and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

AKT3 is altered in 0.17% of thyroid gland carcinoma patients with AKT3 Amplification present in 0.09% of all thyroid gland carcinoma patients [4].

AKT3 Amplification is an inclusion criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 Amplification and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

AKT3 is altered in 0.88% of hematologic and lymphocytic disorder patients with AKT3 Amplification present in 0.07% of all hematologic and lymphocytic disorder patients [4].

AKT3 Amplification is an inclusion criterion in 1 clinical trial for hematologic and lymphocytic disorder, of which 1 is open and 0 are closed. Of the trial that contains AKT3 Amplification and hematologic and lymphocytic disorder as inclusion criteria, 1 is phase 1 (1 open) [5].

AKT3 is altered in 0.47% of hematopoietic and lymphoid system neoplasm patients with AKT3 Amplification present in 0.04% of all hematopoietic and lymphoid system neoplasm patients [4].

AKT3 Amplification is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains AKT3 Amplification and hematopoietic and lymphoid system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

AKT3 is altered in 0.48% of hematopoietic and lymphoid malignancy patients with AKT3 Amplification present in 0.02% of all hematopoietic and lymphoid malignancy patients [4].

AKT3 Amplification is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains AKT3 Amplification and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [5].

AKT3 Amplification is an inclusion criterion in 1 clinical trial for aggressive systemic mastocytosis, of which 1 is open and 0 are closed. Of the trial that contains AKT3 Amplification and aggressive systemic mastocytosis as inclusion criteria, 1 is phase 1 (1 open) [5].

AKT3 Amplification is an inclusion criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 Amplification and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

AKT3 Amplification is an inclusion criterion in 1 clinical trial for classical hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 Amplification and classical hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

AKT3 Amplification is an inclusion criterion in 1 clinical trial for desmoid-type fibromatosis, of which 1 is open and 0 are closed. Of the trial that contains AKT3 Amplification and desmoid-type fibromatosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

AKT3 Amplification is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 Amplification and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

AKT3 is altered in 1.02% of gastric adenocarcinoma patients [4].

AKT3 Amplification is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains AKT3 Amplification and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

AKT3 Amplification is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains AKT3 Amplification and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

AKT3 is altered in 0.46% of liposarcoma patients [4].

AKT3 Amplification is an inclusion criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 Amplification and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

AKT3 Amplification is an inclusion criterion in 1 clinical trial for mast cell leukemia, of which 1 is open and 0 are closed. Of the trial that contains AKT3 Amplification and mast cell leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

AKT3 is altered in 0.95% of multiple myeloma patients [4].

AKT3 Amplification is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 Amplification and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].

AKT3 Amplification is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains AKT3 Amplification and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [5].

AKT3 is altered in 0.04% of myeloid neoplasm patients [4].

AKT3 Amplification is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains AKT3 Amplification and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

AKT3 is altered in 0.82% of osteosarcoma patients [4].

AKT3 Amplification is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 Amplification and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

AKT3 Amplification is an inclusion criterion in 1 clinical trial for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 1 is open and 0 are closed. Of the trial that contains AKT3 Amplification and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 1 is phase 1 (1 open) [5].

AKT3 is altered in 1.4% of undifferentiated pleomorphic sarcoma patients [4].

AKT3 Amplification is an inclusion criterion in 1 clinical trial for undifferentiated pleomorphic sarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 Amplification and undifferentiated pleomorphic sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].